证券日报网讯2月26日，海辰药业（300584）在互动平台回答投资者提问时表示，截至2月13日收盘，公 司股东户数为21135户。 ...

Core Insights - The company has made significant progress in business expansion, product development, and market performance, particularly in the solid-state battery materials sector and lithium battery electrolyte additives [1] Business Development - The company has established a joint venture, Sichuan Luocheng New Materials Technology Co., Ltd., with Sichuan Saike Power to promote the research and industrialization of solid-state battery adhesives and other new energy materials, currently in small-scale or pilot testing [2] - The company is investing in a production capacity of 5,000 tons per year for lithium battery electrolyte additives, with the VC project in preparation for production [2] Product Development - The core product, injectable Labetalol Hydrochloride (including new specifications), successfully renewed its contract and was included in the national medical insurance directory as of December 2025 [3] - New drugs such as Aclidinium Bromide capsules and Sodium Thiosulfate injection were approved in 2025, indicating successful consistency evaluation [3] - The company has also applied for production approval for Acetate Cetrorelix injection, which is currently under review [3] Financial Performance - The company's Q3 2025 report shows revenue of 472 million yuan, a year-on-year increase of 30.80%, and a net profit of 32.68 million yuan, up 16.22% year-on-year, with growth in both revenue and net profit for the third quarter [4] Stock Performance - As of January 16, 2026, the company's stock price increased by 3.26% over the week, with a net inflow of 43.65 million yuan from major funds, indicating active trading [5] - The stock price experienced a limit-up on November 14, 2025, driven by solid-state battery concepts and performance catalysts, highlighting significant divergence between retail and institutional investors [5] Company Status - By the end of Q3 2025, new institutional investors, such as Zhongou Yuexiang Life Mixed Fund, entered the top ten circulating shareholders, reflecting increased investor interest [6] - The number of shareholders showed a slight concentration trend by the end of 2025 [6]

Group 1 - The company, Haitian Pharmaceutical (300584), reported that as of January 30, the number of shareholders was 21,149 [1]

Core Viewpoint - The company has scheduled the disclosure of its 2025 annual report for April 25, 2026, in response to an investor inquiry on the investor interaction platform [2] Group 1 - The company is 海辰药业 (Haitian Pharmaceutical) with stock code 300584.SZ [2] - The inquiry regarding the 2025 performance forecast was made by an investor on the interaction platform [2] - The scheduled date for the 2025 annual report disclosure is April 25, 2026 [2]

Group 1 - The core point of the article highlights that Haisun Pharmaceutical experienced a 5% drop in stock price, trading at 50.30 yuan per share, with a total market capitalization of 6.036 billion yuan as of the report date [1] - Haisun Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, focuses on the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The company's revenue composition is primarily from cardiovascular drugs (87.12%), followed by antibiotics (5.69%), active pharmaceutical ingredients and intermediates (1.68%), digestive drugs (1.50%), antiviral drugs (1.47%), and other categories [1] Group 2 - Among the top circulating shareholders of Haisun Pharmaceutical, the Fuguo Fund's Fuguo Steady Growth Mixed A (010624) fund entered the top ten in the third quarter, holding 700,000 shares, which is 0.85% of the circulating shares [2] - The Fuguo Steady Growth Mixed A fund has a total scale of 6.13 billion yuan, with a year-to-date return of 5.37% and a one-year return of 36.61% [2] - The fund manager, Fan Yan, has been in the position for 10 years and 88 days, with the fund's best return during this period being 187.76% and the worst being -15.11% [3]

Group 1 - The core point of the article is that Haitian Pharmaceutical (300584) reported its number of shareholders as 21,073 as of January 9, 2026 [1]

Group 1 - The core viewpoint of the article is that Haichen Pharmaceutical has achieved the required parameters for its lithium sulfide pilot line products and is preparing to send samples [2] - Sichuan Luocheng is a joint venture between the company's subsidiary Anqing Huichen and Saike Power, focusing on the development of solid-state battery binders [2] - The project is currently in the small-scale development stage [2]

Group 1 - The core viewpoint of the article is that Haichen Pharmaceutical has achieved the required parameters for its lithium sulfide pilot line products and is preparing to send samples [1] - Sichuan Luocheng is a joint venture between the company's subsidiary Anqing Huichen and Saike Power, focusing on the small-scale development of solid-state battery binders [1] - The project is currently still in the small-scale development phase [1]

Group 1 - Company Haitian Pharmaceutical (300584.SZ) announced on January 7 that the parameters of its lithium sulfide pilot line products have met the requirements and samples will soon be sent out [1] - Sichuan Luocheng is a joint venture between the company's subsidiary Anqing Huicheng and Saike Power, which has been closely collaborating on the small-scale development of solid-state battery binders, currently still in the small-scale development phase [1] Group 2 - Investors inquired about the recent acceleration of the industrialization of sulfide solid-state batteries, specifically regarding the current pilot production capacity utilization rate, product purity, and whether samples have been sent to battery companies for verification [2] - Questions were raised about the completion of the small-scale process for the solid-solid contact binder, its bonding strength, and interface impedance, as well as whether Saike Power's experience in battery system integration supports the mass production of the binder [2]

证券代码：300584 证券简称：海辰药业 公告编号：2026-001 南京海辰药业股份有限公司 关于控股股东、实际控制人股份全部解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、股东股份累计被质押的情况 截至公告披露日，曹于平先生及其妻子姜晓群女士所持质押股份情况如下： | | | | 本次解除 | 本次解除 | | | 已质押股份 情况 | | 未质押股份 情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | | 持股 | 质押前质 | 质押后质 | 占其所持 | 占公司总 | | | | | | 名称 | 持股数量 | 比例 | 押股份数 | 押股份数 | 股份比例 | 股本比例 | 已质押股份 限售和冻结 | 占已质押 | 未质押股份 限售和冻结 | 占未质押 | | | | | 量 | 量 | | | 数量 | 股份比例 | 数量 | 股份比例 | | 曹于平 | 50,491,306 | 42.08% | 4,000,00 ...